Prostate-cancer mortality after PSA screening

New England Journal of Medicine

Volumn 366, Issue 23, 2012, Pages 2228-2231

  Djulbegovic, Mia ^a   Neuberger, Molly M ^b   Dahm, Philipp ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER SCREENING; CLINICAL DECISION MAKING; EVIDENCE BASED MEDICINE; HUMAN; LETTER; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; UNITED STATES;

EID: 84861884927     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1204298     Document Type: Letter

References (4)

1. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-90.
2. Screening for prostate cancer: draft recommendation statement. Rockville, MD: U.S. Preventive Services Task Force (http://www. uspreventiveservicestaskforce.org/uspstf12/prostate/draftrecprostate.htm).
3. Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010;341:c4543.
4. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9. [Erratum, N Engl J Med 2009;360:1797.]